Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. (RXST) delivers groundbreaking light adjustable lens technology that transforms post-cataract surgery outcomes. This dedicated news hub provides investors and medical professionals with essential updates on the company's clinical advancements and strategic developments.
Access official press releases covering product innovations, financial performance, and regulatory milestones. Our curated collection includes updates on the Light Adjustable Lens system's clinical adoption, partnership announcements with leading ophthalmology centers, and research breakthroughs in customized vision correction.
Key areas of coverage include quarterly earnings reports, FDA clearances for new device iterations, and peer-reviewed study results validating LAL technology outcomes. Stay informed about manufacturing expansions and international market entries that demonstrate RXST's growth trajectory in the premium intraocular lens sector.
Bookmark this page for real-time updates on how RxSight continues to redefine cataract care through its unique post-operative adjustment capabilities. Monitor critical developments that position the company at the forefront of personalized ophthalmic solutions.
RxSight, Inc. reported strong first quarter 2024 financial results, with a revenue of $29.5 million, a 69% increase compared to the first quarter of 2023. The company sold 20,218 Light Adjustable Lenses (LAL) and 66 Light Delivery Devices (LDD), showing significant growth in procedure volume and unit sales. Gross profit increased to $20.7 million, operating expenses rose to $31.4 million, and the company reported a net loss of $(9.1) million. However, adjusted net loss improved to $(4.4) million. Cash, cash equivalents, and short-term investments were $125.4 million as of March 31, 2024. RxSight raised its 2024 revenue guidance to $132.0 million to $137.0 million, gross margin guidance to 68% to 70%, and operating expense guidance to $126.0 million to $130.0 million.
RxSight, Inc., a medical device company specializing in customized vision after cataract surgery, will be presenting at the Bank of America Healthcare Conference on May 15, 2024. The presentation will be available for viewing online.
FAQ
What is the current stock price of Rxsight (RXST)?
What is the market cap of Rxsight (RXST)?
